Status Accelerates Ability to Bring New Products and Services to Market
- The National Interest Strategic Project certification (“PINES”) was established by the Government of Colombia to prioritize the development of specific projects or companies that are deemed by the Government to be able to significantly increase the national economy
- Khiron’s PINES certification as a Colombian Pharmaceutical Producer of Global Cannabis immediately simplifies and accelerates administration and processes for the Company in executing strategic projects in Colombia and for export
- Under the plan presented to the Government, Khiron will aim to register and introduce more than 4 SKU’s in the Medical Cannabis Category and at least 10 SKU’s in the Consumer Packaged Goods Category (Foods & beverages, supplements, Pets, skin care, etc.), for the domestic market of Colombia and for export of finished products
- Certification demonstrates not only the Government of Colombia’s commitment to the medical cannabis industry in Colombia , but also its support of Khiron’s business plan to create value added products in the medical and CPG cannabis industry for domestic market and for export
- Khiron is one of three companies to obtain this status, placing the Company at the forefront of the industry in Colombia
Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe is pleased to report that the Company has received the status of National Interest Strategic Project (“PINES”) by the Government of Colombia through its Intersectoral Commission for Infrastructure and Strategic Projects (“CIIPE”). The government agency review, and subsequent certification, enables the Company to simplify authorization processes, reduce cost and accelerate time to market for its services and products for the Colombian market and for export purposes.
“The PINES status provides our operations in Colombia with an accelerated path forward to bring new products and services to market. We expect that, through PINES, which is designed to efficiently move projects through the Colombian regulatory process, Khiron will be able to fast track certifications, licenses and permits related to our business, allowing us to accelerate revenue opportunities and add cost efficiencies to our process, while ensuring we continue to bring quality medical cannabis products to more patients in Colombia and globally. We applaud the Government of Colombia on the PINES initiative, which supports the growth of the Colombian economy and encourages the very best industries and businesses we have to offer,” comments Alvaro Torres , Khiron CEO and director.
PINES has historically focused on large, resource sector and infrastructure programs in Colombia , such as the first subway line in Bogota , where programs provide an economic boost to the economy and export capacity, significantly impact job creation, generate positive investment returns, offer operational sustainability, generates large national income or contributes to government planning goals. The declaration of the medical cannabis sector into the program, and in particular Khiron, focuses on the development of pharmaceutical products and the provision of health services with a differentiated and integrative model, demonstrating the government commitment to new industries that advance the economy, adding products that positively transform the quality of life of Colombian patients and in other countries where the Company operates, including the UK, Peru , Germany , and Mexico .
Khiron benefits from the PINES certification by simplifying and accelerating the process for its projects in order to specifically advance: the inclusion of medical cannabis within the list of medications covered by the federal health system, the registration of finished products, currently including four pharmaceutical products and at least 10 CPG SKU’s among others, and export of the health service delivery model to serve potential medical cannabis patients in other countries, and the development of clinical studies and data collection that support the effectiveness and safety of these products.
About Khiron Life Sciences Corp.
Khiron is a vertically integrated medical and CPG cannabis company with core operations in Latin America , and operational activity in Europe and North America. Khiron is the leading cannabis company in Colombia and the first company licensed in Colombia for the cultivation, production, domestic distribution, and international export of both low and high THC medical cannabis products. The Company has further presence in Peru , Mexico , Uruguay , UK, Spain and Germany , where it is positioned to begin sales of medical cannabis.
Leveraging its first-mover advantage, and patient oriented approach, Khiron combines global scientific expertise, product innovation, agricultural infrastructure, wholly-owned medical clinics, and online doctor education programs to drive prescription and brand loyalty to address priority medical conditions. Its Wellbeing unit launched the first branded CBD skincare brand in Colombia , with Kuida TM now marketed in multiple jurisdictions in Latin America , the US and UK. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres , together with an experienced and diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram @khironlife.
This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com . The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
View original content to download multimedia: http://www.prnewswire.com/news-releases/khiron-declared-a-national-strategic-project-by-the-government-of-colombia-301135668.html
SOURCE Khiron Life Sciences Corp.
News Provided by PR Newswire via QuoteMedia
Khiron Life Sciences
ROSEN, LEADING INVESTOR COUNSEL, Reminds Aurora Cannabis Inc. Investors of Important December 1 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – ACB
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.
To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email firstname.lastname@example.org or email@example.com for information on the class action.
HempFusion Wellness Inc. Files Preliminary Prospectus for Initial Public Offering of Common Shares and Units
HempFusion Wellness Inc. (“HempFusion”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that it has filed a preliminary prospectus (the “Preliminary Prospectus”) with the securities regulatory authorities in each of the provinces of Canada, except Quebec, for a proposed initial public offering of (i) common shares of the Company (the “Offered Shares”) for gross proceeds of up to USD$7,000,000 (the “Share Offering”) and (ii) units of the Company (the “Units”) for gross proceeds of up to USD$10,000,000 (the “Unit Offering” and together with the Share Offering, the “Offering”). The offering price of the Offered Shares and the Units (the “Offering Price”) will be determined in the context of the market and is anticipated to be between USD$0.90 and USD$1.35 (the “Offering Price”) per Offered Share and per Unit, respectively.
“We are incredibly excited to announce our initial public offering and HempFusion’s intention to list its securities on the Toronto Stock Exchange. To be the first US-based CBD company to apply to list on the TSX is a tremendous honour,” stated HempFusion’s CEO, Dr. Jason Mitchell N.D. “Completion of this proposed initial public offering will accelerate our ability to scale HempFusion’s operations both domestically and internationally, drive accelerated growth within all our distribution channels, and significantly expand our marketing initiatives,” continued Mitchell.
Trading resumes in:
Company: Harvest Health & Recreation Inc.
** THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.**
Harvest Health & Recreation Inc. (“Harvest” or the “Company”) ( CSE: HARV ), a vertically integrated cannabis company and multi-state operator in the U.S., is pleased to announce that is has entered into an amended agreement with Eight Capital, pursuant to which Eight Capital, together with Canaccord Genuity Corp., as co-lead underwriters and joint bookrunners, together with a syndicate of underwriters (collectively, the “ Underwriters ”), will now purchase on a “bought deal” basis 17,699,200 units of the Company (“the Units ”) at a price of $2.26 per Unit (the “ Offering Price ) for aggregate gross proceeds to Harvest of $40,000,192 (the “ Offering ”). (All figures are in Canadian dollars unless otherwise stated.)
Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) (“Heritage” or the “Company”), is pleased to announce that both Pura Vida and Purefarma tinctures will be available for purchase next week in the province of British Columbia through the province’s authorized Liquor Distribution Branch (“LDB”) channels.
BC Customers will soon be able to purchase Pura Vida Daybreak and Nightfall tinctures as well as Purefarma HLX30 CBD and Balance 15:15. Heritage launched both Pura Vida and Purefarma vape cartridges in September 2020 and the response by customers has been tremendous in the two provinces in which they are available British Columbia and Manitoba.